top of page
Novartis Logo.png
Kisqali Logo.png

Navigating The Challenges of Treating

Breast Cancer in These Evolving Times

1st February 2024 | 18:30 – 20:45 GMT

This meeting is organised and funded by Novartis Pharmaceuticals UK Ltd and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code. It is intended for UK healthcare professionals only.

Company products will be discussed at this meeting and United Kingdom prescribing information is available above.

KISQALI is indicated for the treatment of women with hormone receptor (HR)−positive, human epidermal growth factor receptor 2 (HER2)−negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.* In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.*^

*KISQALI is not recommended to be used in combination with tamoxifen.^

^KISQALI (ribociclib) Summary of Product Characteristics

UK | January 2024 | 378489

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.novartis.com/report

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

bottom of page